Boris Bogomilov, MD
Clinical Cardiac Electrophysiology · Fayetteville, ARNPI 1790749638
Payments from drug & device makers
Across 415 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$2K
- Pfizer$1K
- Abbott$728
- Biosense Webster, Inc.$618
- Novartis$553
- plus $2K from 25 others
Across 1 payment — averaging $200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$200
What the payments were for
- Travel & lodging$2,16924%
- Food & beverage$6,97076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 51 | $2,011 |
| Boston Scientific | 27 | $1,866 |
| Pfizer | 105 | $1,223 |
| Abbott | 22 | $728 |
| Biosense Webster, Inc. | 15 | $618 |
| Novartis | 41 | $553 |
| Johnson & Johnson | 47 | $432 |
| Amgen | 18 | $219 |
| Merck | 13 | $215 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $174 |
| Cvrx, Inc. | 3 | $172 |
| Alnylam Pharmaceuticals Inc. | 7 | $140 |
| Novo Nordisk | 6 | $138 |
| AstraZeneca | 8 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $52 |
| Asahi Intecc USA, Inc. | 5 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Elutia, Inc. | 3 | $42 |
| Bard Peripheral Vascular, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Bayer | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Preventice Services, LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,126
- AVEIR$351
- EMBLEM$271
- Barostim Neo System$138
- Farapulse$119
- AURORA EV-ICD MRI SURESCAN$112
How this compares
$9,140 in reported general payments places this provider in the 15th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
See all clinical cardiac electrophysiology providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,269 | $1,194,230 |
| XareltoRivaroxaban | 476 | $450,622 |
| EntrestoSacubitril/Valsartan | 42 | $43,165 |
| Propafenone Hcl ErPropafenone Hcl | 71 | $19,057 |
| CorlanorIvabradine Hcl | 14 | $12,377 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 479 | $10,689 |
| Dofetilide | 114 | $10,466 |
| Mexiletine Hcl | 83 | $7,239 |
| SotalolSotalol Hcl | 332 | $6,968 |
| Nebivolol Hcl | 127 | $5,682 |
| Metoprolol Succinate | 385 | $5,281 |
| Ivabradine Hcl | 11 | $4,280 |
| Digoxin | 251 | $3,977 |
| Flecainide Acetate | 112 | $3,742 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 42 | $3,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,223 | $1,194,2301,269 claims |
| Johnson & JohnsonXarelto | $432 | $450,622476 claims |
| NovartisEntresto | $553 | $43,16542 claims |
| AmgenCorlanor | $219 | $12,37714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.
Other clinical cardiac electrophysiology in Fayetteville
- Yang YangFayetteville$29K
- Soliman SolimanFayetteville$4K
- Devi NairJonesboro$19.4M
- Monica LoLittle Rock$2.4M
- Mangaraju ChakkaLittle Rock$1.1M
- Sudarone ThihalolipavanLittle Rock$1M
- Gerald GreerLittle Rock$514K
- Thomas WallaceLittle Rock$115K
- Scott BeauLittle Rock$93K
- Oreoluwa OladiranJonesboro$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.